2,6-二氨基嘌呤半硫酸盐 | 69369-16-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 2,6-二氨基嘌呤半硫酸盐
• 中文别名: 2,5-双(5-叔丁基-1,3-苯并噁唑-2-基)噻酚；2,6-二氨基嘌呤硫酸盐水合物
• 英文名称: 2,6-Diaminopurine hemisulfate salt
• 英文别名: 7H-purine-2,6-diamine;sulfuric acid
• CAS: 69369-16-0
• 化学式: C10H14N12O4S
• mdl: MFCD00013156
• 分子量: 398.37
• InChiKey: HNHVJLBUCSUIFH-UHFFFAOYSA-N

物化性质

• 熔点：
  >225°C (dec.)
• 溶解度：
  适度溶解于酸水溶液

计算性质

• 辛醇/水分配系数(LogP)：
  -0.72
• 重原子数：
  27
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  296
• 氢给体数：
  8
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  、 2,6-二氨基嘌呤半硫酸盐 、 三羟甲基氨基甲烷盐酸盐 反应 2.0h， 以The concentration of 2,6-diaminopurine-2′-deoxyriboside produced in the reaction solution的产率得到2,6-二氨基嘌呤-2'-脱氧核苷
  参考文献：
  名称：

  Process for preparing 2,6-diaminopurine-2′-deoxyriboside and 2′-deoxyguanosine

  摘要：

  一种制备2,6-二氨基嘌呤-2'-脱氧核苷和2'-脱氧鸟嘌呤核苷的工艺。这些化合物可用作制药原料，如抗病毒剂等，并特别作为反义寡核苷酸的起始材料。

  公开号：

  US06197552B1

文献信息

• Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
  申请人：Renzi Paolo

  公开号：US20050032723A1

  公开（公告）日：2005-02-10

  The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.

  本发明涉及核苷酸替代物在提高核酸分子体内效力以及抑制哺乳动物炎症方面的用途。更具体地说，本发明涉及 2′6′二氨基嘌呤（DAP）及其类似物本身在抗炎组合物中的用途，还涉及制备与传统寡核苷酸相比具有更高的体内生理效率和更低的毒性的核酸分子。本发明特别适用于制备治疗肺/呼吸道疾病的反义寡核苷酸，如囊性纤维化、哮喘、慢性支气管炎、慢性阻塞性肺病、嗜酸性支气管炎、过敏、过敏性鼻炎、肺纤维化、成人呼吸窘迫综合征、鼻窦炎、呼吸道合胞病毒或其他病毒性呼吸道感染和癌症。
• METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS
  申请人：Topigen Pharmaceuticals Inc.

  公开号：EP1406667B1

  公开（公告）日：2008-02-20
• METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS
  申请人：Topigen Pharmaceutiques Inc

  公开号：EP1406667A2

  公开（公告）日：2004-04-14
• METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS
  申请人：RENZI Paolo

  公开号：US20100286235A1

  公开（公告）日：2010-11-11

  The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′ diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.
• US7745420B2
  申请人：——

  公开号：US7745420B2

  公开（公告）日：2010-06-29